DALLAS, July 24, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring drug-three patch therapies maker BioElectronics Corp. (Pink Sheets:BIEL). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on BioElectronics Corp. (Pink Sheets:BIEL) should be of particular interest to other healthcare-related companies: ICU Medical Inc. (Nasdaq:ICUI), Bio-Matrix Scientific Group Inc. (OTCBB:BMSN), AngioDynamics Inc. (Nasdaq:ANGO) and SenoRX Inc. (Nasdaq:SENO).
It is available at: http://www.beaconequity.com/i/BIEL
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
BioElectronics Corp. develops and markets drug-free, anti-inflammatory patch therapies to treat a variety of medical conditions. Sold under the ActiPatch Therapy name, the patch delivers pulsed electromagnetic field therapy to affect pain relief from inflamed areas of the body. Through its miniaturized microchip, power source and antenna, the ActiPatch Therapy product delivers a pulsed radio frequency signal of 27 megahertz (MHz) into the body's affected area to induce a low frequency electromagnetic field to damaged tissue cells.
In the report, the analyst notes:
"The Company's strength comes from the weakness in the top three over-the-counter drugs acetaminophen (Tylenol) made by Johnson & Johnson, Bayer's acetylsalicylic acid (Aspirin), and ibuprofen (Advil) made by Wyeth.
"The Company has upgraded its product, ironed-out product issues by moving its manufacturing to China, and expanded its distribution relationships worldwide. With overhead low, gross margins anticipated to reach 75%, according to BIEL chairman of the board, Rick Anderson, and almost no debt, the Company is poised to be profitable following FDA approvals and widespread public acceptance, according to Anderson."
To read the entire report visit: http://www.beaconequity.com/i/BIEL
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.